Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer Meeting Abstract

  

Authors:	DeMichele, A. M.; Clark, A. S.; Holmes, R.; Volpe, M.; Medrano, C.; Troxel, A.; Fox, K.; Domchek, S.; Matro, J.; Bradbury, A.; Shih, N.; Feldman, M.; Hexner, E.; Bromberg, J.
Abstract Title:	Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
Meeting Title:	2016 San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	77
Issue:	4 Suppl.
Meeting Dates:	2016 Dec 6-10
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2017-02-01
Language:	English
ACCESSION:	WOS:000397999001029
DOI:	10.1158/1538-7445.sabcs16-p2-08-03
PROVIDER:	wos
Notes:	Meeting Abstract: P2-08-03 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/109936